ARTES steps further into the vaccine business by acquiring Anavax

ARTES Biotech­nol­o­gy announces today the acquire­ment of the ANAVAX virus-like par­ti­cle (VLP) tech­nol­o­gy from Select Vac­cines Ltd. ANAVAX is a patent-pro­­tec­t­ed VLP tech­nol­o­gy that can be applied to the pre­ven­tion of sev­er­al infec­tious dis­eases. With the com­bi­na­tion of two excel­lent tech­nol­o­gy plat­forms, ANAVAX and the Hansenu­la expres­sion sys­tem, ARTES has posi­tioned itself as a unique […]

Injectable Sustained Release Formulations of Therapeutic Proteins

Q Chip Ltd and ARTES Biotech­nol­o­gy GmbH announce that they have signed a Col­lab­o­ra­tive Agree­ment to explore the co-devel­op­­­ment of a new sus­tained release for­mu­la­tion of inter­fer­on alpha 2a for the treat­ment of chron­ic hepati­tis B and C. The study is designed to eval­u­ate Q Chip’s Q‑Sphera™ pep­tide and pro­tein deliv­ery plat­form to devel­op a […]

ARTES and Rhein Minapharm continue their successful product development collaboration

Lan­gen­feld and Cairo – ARTES Biotech­nol­o­gy and Rhein Minapharm Bio­genet­ics joint­ly announced the suc­cess­ful pro­duc­tion of a new tar­get of a ther­a­peu­tic pro­tein. This is the first result of a long-term research col­lab­o­ra­tion that was signed in Jan­u­ary 2008. Con­se­quent­ly, the two com­pa­nies extend­ed their col­lab­o­ra­tion in May 2009. ARTES applied its pro­pri­etary Hansenu­la tech­nol­o­gy […]